NuGEN 2014 Genomics Grant Challenge announced

NewsGuard 100/100 Score

NuGEN Technologies, Inc., a market leader in the development of innovative sample preparation solutions for Next Generation Sequencing (NGS) applications, has announced the NuGEN 2014 Genomics Grant Challenge.

This is the fourth year that NuGEN has funded a $10,000 grant challenge. "This program has been well-received by the scientific community year after year, and we expect the grant challenge for target enrichment-focused studies to draw strong participation this year," commented Doug Amorese, VP of R&D for NuGEN. "We look forward to receiving the study proposals and to catalyzing research efforts that may be stalled due to lack of funding. We were impressed by the high caliber of study designs received last year."

"There are many promising research projects that don't receive NIH grants, as funding has been more difficult to secure in recent years," stated Elizabeth Hutt, CEO of NuGEN. "We are pleased to play a role in supporting biomedical research again this year with the Genomics Grant Challenge. Enabling genomic research projects to move forward not only advances discovery, but benefits the broader community. Through this initiative we are able to demonstrate our on-going commitment to life science."

NuGEN is accepting non-confidential study proposals until July 31, 2014. All abstract submission will be reviewed and the winning proposal will be selected by a scientific committee, with the winner being notified on August 28, 2014. The 2014 Genomics Grant Challenge Award recipient will receive up to $10,000 of Ovation® Target Enrichment System reagents for targeted sequencing studies.

Source:

NuGEN Technologies, Inc.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Baylor study reveals role of newly inherited DNA variants in recessive diseases